Compass therapeutics announces first patient dosed in an investigator sponsored trial of tovecimig in the first-line setting for patients with biliary tract cancer

Boston, april 21, 2025 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an investigator sponsored trial (ist) to evaluate tovecimig (ctx-009, a dll4 x vegf-a bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (btc). the ist is being conducted at the university of texas md anderson cancer center.
CMPX Ratings Summary
CMPX Quant Ranking